tiprankstipranks
Protagenic Therapeutics (PTIX)
NASDAQ:PTIX
Holding PTIX?
Track your performance easily

Protagenic Therapeutics (PTIX) Income Statement

31 Followers

Protagenic Therapeutics Income Statement

Last quarter (Q ), Protagenic Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Protagenic Therapeutics's net income was $-640.78K. See Protagenic Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 1.79M$ 4.53M$ 3.56M$ 4.14M$ 2.55M$ 2.09M
Operating Income
$ -5.27M$ -4.53M$ -3.60M$ -4.14M$ -2.55M$ -2.09M
Net Non Operating Interest Income Expense
$ 75.24K$ 156.79K$ 48.33K$ -463.70K$ -245.68K$ 343.86K
Other Income Expense
$ 478.18K$ -630.32K$ 421.74K$ -83.67K$ -248.55K$ -335.22K
Pretax Income
$ -5.65M$ -5.00M$ -3.56M$ -4.52M$ -2.55M$ -1.75M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -5.65M$ -5.00M$ -3.98M$ -4.52M$ -2.55M$ -1.75M
Basic EPS
$ -1.27$ -1.15$ -0.82$ -1.24$ -1.00-
Diluted EPS
$ -1.27$ -1.15$ -0.82$ -1.24$ -1.00$ -0.68
Basic Average Shares
$ 17.81M$ 4.34M$ 4.32M$ 3.69M$ 2.58M$ 2.57M
Diluted Average Shares
$ 17.81M$ 4.34M$ 4.32M$ 3.69M$ 2.58M$ 2.57M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 1.79M$ 4.53M$ 3.56M$ 4.14M$ 2.55M$ 2.09M
Net Income From Continuing And Discontinued Operation
$ -5.65M$ -5.00M$ -3.56M$ -4.52M$ -2.55M$ -1.75M
Normalized Income
$ -3.55M$ -3.95M-$ -3.57M--
Interest Expense
------
EBIT
$ -2.16M$ -4.89M$ -3.42M$ -4.03M$ -2.30M$ -1.75M
EBITDA
$ -2.08M$ -4.86M$ -3.31M$ -4.03M$ -2.30M$ -1.74M
Currency in USD

Protagenic Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis